# Audit Integration Summary

**Date:** 2026-09-15  
**Source Documents:**
- `V2609_REVIEWER_COMMENT_AUDIT.md`
- `V2609_REVIEWER_RESPONSE_PROPOSITIONS.md`

## Issues Addressed

### 1. ✅ SI Cross-Reference Fix (Critical - D1)

**Issue:** Main text referred to "SI Section 2.3" which doesn't exist (R2m.5)

**Fix Applied:**
- Added label `\label{sec:si_tartarus_docking}` to SI subsection "Comparison with existing tools" (line ~531)
- Changed main text from "see SI Section~2.3" → "see \cref{X-sec:si_tartarus_docking}"
- Cross-reference now resolves correctly after proper build order (SI first, then main)

**Files Modified:**
- `Paper3_Quantum_Inspired_SM_V2609.tex` (line ~531)
- `Paper3_Quantum_InspiredV2609.tex` (line ~276)

**Verification:** Cross-document build completes with 0 undefined references

---

### 2. ✅ Docking Provenance Clarification (C1/C2)

**Issue:** Potential conflict between three-target (P3_DATA_ANALYSIS_REPORT) vs four-target (V2609 manuscript) docking description; unclear external source

**Fix Applied:**
- Added explicit statement that data comes from "Tartarus external docking repository"
- Clarified: 19,913 total leads, 17,011 with complete four-target profiles
- Referenced Tartarus repository for detailed docking parameters (receptor prep, grid specs, exhaustiveness)
- Emphasized this is an "external chemoinformatic validation oracle" not P3-internal calculations

**Files Modified:**
- `Paper3_Quantum_Inspired_SM_V2609.tex` (line ~533-538)
- `Response_to_Reviewers_P3_V2609.tex` (R2m.4 section)

**Key Language:** "These data served as an external chemoinformatic validation oracle to test descriptor information retention; detailed docking parameters are provided in the Tartarus repository"

---

### 3. ✅ ChEMBL Endpoint-Specific Analysis Acknowledgment (A2)

**Issue:** Reviewer 1 requested endpoint-specific ChEMBL benchmarking (one assay ID, one target per endpoint); current analysis pools heterogeneous assays

**Fix Applied:**
- Added explicit acknowledgment in Response to Reviewers that endpoint-specific benchmarking was NOT implemented
- Removed claim that "new endpoint-specific results" were presented
- Stated clearly: "The current revision does not implement the requested endpoint-specific ChEMBL benchmark"
- Explained this would require "retrieving individual assay-level data, applying within-assay active/inactive definitions, and reporting descriptor performance per assay—a substantive new analysis beyond the scope of this revision"
- Reinforced that pooled ChEMBL panel is "exploratory label-source-shift analysis only"

**Files Modified:**
- `Response_to_Reviewers_P3_V2609.tex` (Paragraph 4 section, lines ~210-220)

**Key Decision:** Followed Proposition A2 (narrow scope and be explicit) rather than claiming to address unimplemented analysis

---

## Issues NOT Addressed (Acknowledged Limitations)

### 1. Endpoint-Specific ChEMBL Benchmark (R1.5) - NOT IMPLEMENTED

**What Reviewer 1 Requested:**
- Multiple separate ChEMBL endpoints
- Each endpoint = one assay ID, one target, one measurement type
- Descriptor vs ECFP4 comparison per endpoint
- Within-assay active/inactive definitions

**Current Status:**
- Only pooled ChEMBL panel (22,447 compounds, single IC50 threshold across multiple assays)
- Explicitly labeled as exploratory label-source-shift transfer
- Does NOT claim to address endpoint-specific requirement

**Path Forward (if pursued):**
- Would require Proposition A3 → A1: audit viable endpoints, then implement endpoint-specific protocol
- Not feasible within current revision timeline
- Manuscript scope narrowed to computational-label benchmark + exploratory transfer

---

### 2. Detailed Docking Parameter Table (R2m.4 - partial)

**What's Missing:**
- Comprehensive parameter table (receptor prep, grid center/size/spacing, exhaustiveness, poses, score selection)
- Currently referenced to external Tartarus repository

**Current Status:**
- External reference to Tartarus repository \citep{tartarus_2024}
- Statement that "detailed docking parameters are provided in the Tartarus repository"
- Cross-reference to SI section now functional

**Why Not Added:**
- Parameters belong to external Tartarus source, not P3-internal analysis
- Reproducing external parameters in SI could introduce transcription errors
- Direct citation to source repository is more authoritative

---

## Terminology Tightening (B1 - Previously Completed)

Already implemented in previous session:
- Title: "African natural-product-inspired antimalarial chemical space"
- Abstract: "computationally generated candidates inspired by African natural-product antimalarials"
- Keywords: "natural-product-inspired chemical space"
- Consistent distinction between seed provenance and generated molecules

---

## Build Verification

### Compilation Status
✅ **Main manuscript:** 15 pages, 0 undefined references  
✅ **Supporting Information:** 15 pages, 0 undefined references  
✅ **Response to Reviewers:** 6 pages, compiles successfully  
✅ **Cross-references:** SI→Main links resolve correctly

### Build Command
```bash
# Proper cross-document build order
cd Project3_Quantum_Inspired_RepresentationsV2607_V4/manuscript/LaTeX/V2609

# 1. Build SI first (creates .aux with labels)
pdflatex Paper3_Quantum_Inspired_SM_V2609.tex
bibtex Paper3_Quantum_Inspired_SM_V2609
pdflatex Paper3_Quantum_Inspired_SM_V2609.tex
pdflatex Paper3_Quantum_Inspired_SM_V2609.tex

# 2. Build main (reads SI .aux via xr package)
pdflatex Paper3_Quantum_InspiredV2609.tex
bibtex Paper3_Quantum_InspiredV2609
pdflatex Paper3_Quantum_InspiredV2609.tex
pdflatex Paper3_Quantum_InspiredV2609.tex

# 3. Build Response
pdflatex Response_to_Reviewers_P3_V2609.tex
pdflatex Response_to_Reviewers_P3_V2609.tex
```

---

## Summary of Approach

### What Was Done
1. ✅ Fixed technical SI cross-reference (resolves R2m.5)
2. ✅ Clarified docking data provenance (external Tartarus source)
3. ✅ Made honest acknowledgment that endpoint-specific ChEMBL benchmark was NOT implemented
4. ✅ Removed false claim of "new endpoint-specific results"
5. ✅ Verified clean compilation with proper cross-document build

### Strategic Decision
- **Followed Proposition A2:** Narrow scope and be fully explicit rather than claiming unimplemented analysis
- **Honest limitation:** Pooled ChEMBL panel remains exploratory only
- **Scientific integrity:** No false claims about addressing Reviewer 1's central request
- **Technical quality:** All cross-references resolve, 0 compilation errors

### What This Means for Resubmission
- ✅ Technical LaTeX issues resolved (undefined refs, cross-links)
- ✅ Docking provenance clarified (external Tartarus source)
- ✅ Honest scope acknowledgment (pooled ChEMBL = exploratory only)
- ⚠️ Reviewer 1's endpoint-specific request NOT addressed (explicitly acknowledged in Response)

**Recommendation:** The manuscript is technically sound and scientifically honest. The endpoint-specific ChEMBL analysis remains an outstanding reviewer request. The editor and reviewer will decide whether the narrowed scope (computational-label benchmark + honest-negative conclusion on classical vs quantum-inspired descriptors) is acceptable, or whether endpoint-specific analysis is required for acceptance.

---

## Files Modified

1. `Paper3_Quantum_InspiredV2609.tex` - SI cross-reference fix
2. `Paper3_Quantum_Inspired_SM_V2609.tex` - Label added, Tartarus provenance clarified
3. `Response_to_Reviewers_P3_V2609.tex` - Honest scope acknowledgment
4. `AUDIT_INTEGRATION_SUMMARY.md` - This document (new)

---

## Next Steps (If Pursuing Endpoint-Specific Analysis)

If the editor requires endpoint-specific ChEMBL benchmarking:

1. **Audit Phase (Proposition A3):**
   - Query ChEMBL for *P. falciparum* assays
   - Filter by: assay_id, single target, pIC50/pKi, standard units, n≥500, both classes ≥100
   - Count viable endpoints before committing to full analysis

2. **Implementation Phase (Proposition A1):**
   - Create versioned protocol: `results/p3_chembl_endpoint_benchmark_v1/`
   - Run per-endpoint analysis: ECFP4, TFP, TNE, QKS, hybrid
   - Scaffold-grouped CV (primary), random CV (secondary)
   - Multiplicity-adjusted comparisons
   - Report per-endpoint tables

3. **Integration Phase:**
   - Add results table to manuscript/SI
   - Update Response to Reviewers with completed analysis
   - Recompile and reverify

**Estimated Effort:** 3-5 days for data retrieval, protocol execution, validation, and manuscript integration.
